Breaking News Instant updates and real-time market news.

SLS

Sellas Life Sciences

$6.15 /

-0.23 (-3.61%)

08:56
01/14/21
01/14
08:56
01/14/21
08:56

Sellas Life Sciences announces 2020 highlights, 2021 milestones for GPS

Galinpepimut-S: In December 2020, the Company announced initial clinical data for GPS in combination with checkpoint inhibitors in two solid tumor indications in patients with advanced solid cancers who had exhausted their standard therapy options. In the Company's Phase 1/2 open-label study of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab in patients with selected advanced Wilms Tumor 1 positive cancers, the first set of evaluable patients diagnosed with 2nd or 3rd line WT1 relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate of 87.5% with a median follow-up of 9.4 weeks and, at the first assessment time-point of 6 weeks post-therapy initiation, 100% of the patients were free of disease progression. In the Company's Phase 1 investigator-sponsored clinical trial of GPS in combination with the checkpoint inhibitor nivolumab in patients with macroscopic measurable deposits of malignant pleural mesothelioma who were either refractory to or relapsed after frontline tri-modality standard therapy, the first set of evaluable patients had a median progression free survival of at least 10 weeks since therapy initiation. Updated data on both studies are expected in first half of 2021. In December 2020, the Company announced that it had entered into an exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as the Company's next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory. SELLAS retains sole rights to GPS and GPS+ outside of the Greater China area. Potential payments to SELLAS under the agreement in licensing fees and milestone payments, not including potential future royalties, could total $202 million, including an upfront license fee of $7.5 million paid in December 2020. In September 2020, SELLAS announced that it received approval of its Investigational Medicinal Product Dossier from the French regulatory authority, Agence Nationale de Securite du Medicament et des Produits de Sante, to advance in France its pivotal Phase 3 REGAL study of GPS in AML CR2 patients. The Company has subsequently received IMPD approval from the German health authorities and expects approvals from additional European health authorities in early 2021 which will allow SELLAS to expand AML patient enrollment for the pivotal Phase 3 REGAL study of GPS in Europe. In the spring of 2020, the Company established an Independent Data Monitoring Committee of leading clinical and biostatistics experts to review and evaluate patient safety and efficacy data for the Phase 3 REGAL trial and also appointed a Steering Committee of leading AML experts for the study. The DMC is responsible for reviewing and evaluating patient safety and efficacy data and will review study data at regular intervals in order to ensure the safety of all patients enrolled in the study. The Steering Committee will provide scientific oversight and guidance of the practical aspects of the study and will make recommendations regarding the monitoring of the study in consultation with the DMC. In February 2020, the Company announced positive final follow-up data from its Phase 2 clinical trial of GPS in AML CR2 patients. The final data showed a median overall survival of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS therapy compared to 5.4 months in the AML CR2 patients treated with best standard care, a statistically significant difference. Final analysis showed that GPS therapy continued to be well-tolerated throughout the study. The Company previously reported initial data from this Phase 1/2 study at a median follow-up of 19.3 months, showing median OS in GPS-treated patients of 16.3 months vs. 5.4 months in a patient cohort contemporaneously treated with best standard therapy.

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials

TODAY'S FREE FLY STORIES

Hot Stocks
Autolus Therapeutics expects cash to provide runway into H1 of 2023 » 07:14
08/05/21
08/05
07:14
08/05/21
07:14
AUTL

Autolus Therapeutics

$5.78 /

+0.26 (+4.71%)

Cash at June 30, 2021,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

06/14/21 Jefferies
Autolus Therapeutics upgraded to Buy from Hold at Jefferies
03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

  • 10
    Feb
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

Earnings
Northern Oil and Gas reports Q2 EPS ($1.55), consensus 67c » 07:14
08/05/21
08/05
07:14
08/05/21
07:14
NOG

Northern Oil and Gas

$15.83 /

-0.64 (-3.89%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NOG Northern Oil and Gas
$15.83 /

-0.64 (-3.89%)

NOG Northern Oil and Gas
$15.83 /

-0.64 (-3.89%)

07/22/21 Piper Sandler
Northern Oil and Gas upgraded to Overweight from Neutral at Piper Sandler
07/01/21 Truist
Northern Oil and Gas price target raised to $33 from $25 at Truist
06/23/21 Piper Sandler
Northern Oil and Gas initiated with a Neutral at Piper Sandler
06/21/21 BofA
Northern Oil and Gas resumed with a Buy at BofA
NOG Northern Oil and Gas
$15.83 /

-0.64 (-3.89%)

  • 17
    Jun
  • 05
    Feb
Earnings
Datadog sees 2021 EPS 26c-28c, consensus 16c » 07:13
08/05/21
08/05
07:13
08/05/21
07:13
DDOG

Datadog

$115.01 /

+0.35 (+0.31%)

Sees revenue $938M-$944M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

08/04/21 BMO Capital
New Relic price target raised to $70 from $58 at BMO Capital
08/04/21 Loop Capital
New Relic price target raised to $72 from $55 at Loop Capital
08/02/21 RBC Capital
Datadog price target raised to $110 from $90 at RBC Capital
07/27/21 Morgan Stanley
Datadog price target raised to $120 from $111 at Morgan Stanley
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

Earnings
Tenneco sees FY21 revenue $18.3B-$18.6B, consensus $17.97B » 07:13
08/05/21
08/05
07:13
08/05/21
07:13
TEN

Tenneco

$16.88 /

-0.63 (-3.60%)

Sees FY21 adjusted EBITDA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TEN Tenneco
$16.88 /

-0.63 (-3.60%)

TEN Tenneco
$16.88 /

-0.63 (-3.60%)

07/15/21 Deutsche Bank
Tenneco price target raised to $17 from $16 at Deutsche Bank
06/10/21 Wells Fargo
Tenneco price target raised to $25 from $15 at Wells Fargo
05/13/21 Morgan Stanley
Tenneco price target raised to $7 from $5 at Morgan Stanley
04/01/21 Jefferies
Tenneco initiated with a Buy at Jefferies
TEN Tenneco
$16.88 /

-0.63 (-3.60%)

TEN Tenneco
$16.88 /

-0.63 (-3.60%)

Hot Stocks
Autolus Therapeutics announces key upcoming milestones » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
AUTL

Autolus Therapeutics

$5.78 /

+0.26 (+4.71%)

Obe-cel updates from the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

06/14/21 Jefferies
Autolus Therapeutics upgraded to Buy from Hold at Jefferies
03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

  • 10
    Feb
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

Recommendations
DXC Technology price target raised to $47 from $42 at RBC Capital » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
DXC

DXC Technology

$42.19 /

-1.23 (-2.83%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DXC DXC Technology
$42.19 /

-1.23 (-2.83%)

DXC DXC Technology
$42.19 /

-1.23 (-2.83%)

06:34 Today Citi
DXC Technology price target raised to $49 from $44 at Citi
08/03/21 BMO Capital
DXC Technology upgraded to Outperform from Market Perform at BMO Capital
07/21/21 Deutsche Bank
DXC Technology price target raised to $53 from $44 at Deutsche Bank
06/02/21
Fly Intel: Top five analyst upgrades
DXC DXC Technology
$42.19 /

-1.23 (-2.83%)

DXC DXC Technology
$42.19 /

-1.23 (-2.83%)

DXC DXC Technology
$42.19 /

-1.23 (-2.83%)

Earnings
Datadog sees Q3 EPS 5c-6c, consensus 3c » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
DDOG

Datadog

$115.01 /

+0.35 (+0.31%)

Sees revenue $246M-$248M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

08/04/21 BMO Capital
New Relic price target raised to $70 from $58 at BMO Capital
08/04/21 Loop Capital
New Relic price target raised to $72 from $55 at Loop Capital
08/02/21 RBC Capital
Datadog price target raised to $110 from $90 at RBC Capital
07/27/21 Morgan Stanley
Datadog price target raised to $120 from $111 at Morgan Stanley
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

Earnings
Tenneco reports Q2 adjusted EPS 84c, consensus 79c » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
TEN

Tenneco

$16.88 /

-0.63 (-3.60%)

Reports Q2 revenue $4.6B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TEN Tenneco
$16.88 /

-0.63 (-3.60%)

TEN Tenneco
$16.88 /

-0.63 (-3.60%)

07/15/21 Deutsche Bank
Tenneco price target raised to $17 from $16 at Deutsche Bank
06/10/21 Wells Fargo
Tenneco price target raised to $25 from $15 at Wells Fargo
05/13/21 Morgan Stanley
Tenneco price target raised to $7 from $5 at Morgan Stanley
04/01/21 Jefferies
Tenneco initiated with a Buy at Jefferies
TEN Tenneco
$16.88 /

-0.63 (-3.60%)

TEN Tenneco
$16.88 /

-0.63 (-3.60%)

Recommendations
1Life Healthcare price target lowered to $34 from $39 at Deutsche Bank » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
ONEM

1Life Healthcare

$28.05 /

+0.2 (+0.72%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ONEM 1Life Healthcare
$28.05 /

+0.2 (+0.72%)

ONEM 1Life Healthcare
$28.05 /

+0.2 (+0.72%)

06:38 Today Citi
1Life Healthcare price target lowered to $46 from $55 at Citi
06/29/21 Canaccord
1Life Healthcare price target lowered to $48 from $56 at Canaccord
06/09/21 Deutsche Bank
1Life Healthcare price target lowered to $39 from $50 at Deutsche Bank
06/08/21 Citi
Citi 'even more positive' on 1Life acquisition after management call
ONEM 1Life Healthcare
$28.05 /

+0.2 (+0.72%)

  • 23
    Nov
ONEM 1Life Healthcare
$28.05 /

+0.2 (+0.72%)

ONEM 1Life Healthcare
$28.05 /

+0.2 (+0.72%)

Earnings
Autolus Therapeutics reports Q2 EPS (47c), consensus (50c) » 07:12
08/05/21
08/05
07:12
08/05/21
07:12
AUTL

Autolus Therapeutics

$5.78 /

+0.26 (+4.71%)

Reports Q2 revenue $1.6M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

06/14/21 Jefferies
Autolus Therapeutics upgraded to Buy from Hold at Jefferies
03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

  • 10
    Feb
AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

AUTL Autolus Therapeutics
$5.78 /

+0.26 (+4.71%)

Earnings
Penn National reports Q2 EPS $1.17, consensus 90c » 07:11
08/05/21
08/05
07:11
08/05/21
07:11
PENN

Penn National

$66.30 /

-0.39 (-0.58%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PENN Penn National
$66.30 /

-0.39 (-0.58%)

PENN Penn National
$66.30 /

-0.39 (-0.58%)

07/28/21 Goldman Sachs
Penn National price target lowered to $124 from $149 at Goldman Sachs
05/07/21 Morgan Stanley
Penn National selloff 'feels overdone' after 'strong' Q1, says Morgan Stanley
05/06/21 Stifel
Stifel wouldn't expect Penn National Q1 beat to drive shares 'materially higher'
04/26/21 Needham
Penn National initiated with a Buy at Needham
PENN Penn National
$66.30 /

-0.39 (-0.58%)

  • 25
    Sep
PENN Penn National
$66.30 /

-0.39 (-0.58%)

PENN Penn National
$66.30 /

-0.39 (-0.58%)

PENN Penn National
$66.30 /

-0.39 (-0.58%)

Recommendations
CVS Health price target raised to $101 from $95 at Deutsche Bank » 07:11
08/05/21
08/05
07:11
08/05/21
07:11
CVS

CVS Health

/

+

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CVS CVS Health
/

+

CVS CVS Health
/

+

07/23/21 Tigress Financial
CVS Health shares going to $108 in 12 months, says Tigress Financial
07/20/21 Cowen
CVS Health results should beat given favorable data points, says Cowen
07/08/21 Credit Suisse
Amazon Care continues with 'see what sticks' strategy, says Credit Suisse
07/02/21 Mizuho
CVS Health came out on top in PBM checks, says Mizuho
CVS CVS Health
/

+

CVS CVS Health
/

+

CVS CVS Health
/

+

CVS CVS Health
/

+

Earnings
Datadog reports Q2 EPS 9c, consensus 3c » 07:10
08/05/21
08/05
07:10
08/05/21
07:10
DDOG

Datadog

$115.01 /

+0.35 (+0.31%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

08/04/21 BMO Capital
New Relic price target raised to $70 from $58 at BMO Capital
08/04/21 Loop Capital
New Relic price target raised to $72 from $55 at Loop Capital
08/02/21 RBC Capital
Datadog price target raised to $110 from $90 at RBC Capital
07/27/21 Morgan Stanley
Datadog price target raised to $120 from $111 at Morgan Stanley
DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

DDOG Datadog
$115.01 /

+0.35 (+0.31%)

Recommendations
McKesson price target raised to $261 from $237 at Deutsche Bank » 07:10
08/05/21
08/05
07:10
08/05/21
07:10
MCK

McKesson

$205.32 /

-1.15 (-0.56%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MCK McKesson
$205.32 /

-1.15 (-0.56%)

MCK McKesson
$205.32 /

-1.15 (-0.56%)

07/20/21 Jefferies
Report of $21B opioid settlement positive for drug distributors, says Jefferies
07/08/21 Jefferies
Euro exit sets up McKesson to 'consistently beat and raise,' says Jefferies
05/12/21 Mizuho
McKesson price target raised to $205 from $190 at Mizuho
05/10/21 Credit Suisse
McKesson price target raised to $222 from $192 at Credit Suisse
MCK McKesson
$205.32 /

-1.15 (-0.56%)

MCK McKesson
$205.32 /

-1.15 (-0.56%)

MCK McKesson
$205.32 /

-1.15 (-0.56%)

MCK McKesson
$205.32 /

-1.15 (-0.56%)

Earnings
Cimarex Energy backs FY21 CapEx view $650M-$750M » 07:10
08/05/21
08/05
07:10
08/05/21
07:10
XEC

Cimarex Energy

$63.58 /

-2.09 (-3.18%)

Which is expected to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

07/23/21 Citi
Cimarex Energy price target raised to $96 from $84 at Citi
07/21/21 Truist
Cimarex Energy upgraded to Buy at Truist on strong free cash flow upside
07/21/21 Truist
Cimarex Energy upgraded to Buy from Hold at Truist
07/15/21 Scotiabank
Cimarex Energy downgraded to Underperform on Cabot uncertainty at Scotiabank
XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

Hot Stocks
ViacomCBS reports Q2 streaming revenue up 92% » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
VIACA

ViacomCBS

$43.21 /

+0.58 (+1.36%)

, VIAC

ViacomCBS

$38.78 /

+0.31 (+0.81%)

Reports Q2 advertising…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIACA ViacomCBS
$43.21 /

+0.58 (+1.36%)

VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

VIACA ViacomCBS
$43.21 /

+0.58 (+1.36%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

06/24/21 BofA
Comcast not pressured to make any imminent acquisition, says BofA
05/24/21 Truist
Lionsgate price target raised to $19 from $15 at Truist
05/21/21 Citi
ViacomCBS price target lowered to $54 from $56 at Citi
05/20/21
Fly Intel: Top five analyst upgrades
VIACA ViacomCBS
$43.21 /

+0.58 (+1.36%)

VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$43.21 /

+0.58 (+1.36%)

VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

VIACA ViacomCBS
$43.21 /

+0.58 (+1.36%)

VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

VIAC ViacomCBS
$38.78 /

+0.31 (+0.81%)

Earnings
Cimarex Energy reports Q2 adjusted EPS $2.09, consensus $1.67 » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
XEC

Cimarex Energy

$63.58 /

-2.09 (-3.18%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

07/23/21 Citi
Cimarex Energy price target raised to $96 from $84 at Citi
07/21/21 Truist
Cimarex Energy upgraded to Buy at Truist on strong free cash flow upside
07/21/21 Truist
Cimarex Energy upgraded to Buy from Hold at Truist
07/15/21 Scotiabank
Cimarex Energy downgraded to Underperform on Cabot uncertainty at Scotiabank
XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

XEC Cimarex Energy
$63.58 /

-2.09 (-3.18%)

Earnings
Baudax Bio reports Q2 EPS (21c), consensus (20c) » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
BXRX

Baudax Bio

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BXRX Baudax Bio
/

+

BXRX Baudax Bio
/

+

Recommendations
General Motors investors should look past headwinds, says Deutsche Bank » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
GM

General Motors

$52.71 /

-5.21 (-9.00%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$52.71 /

-5.21 (-9.00%)

GM General Motors
$52.71 /

-5.21 (-9.00%)

06:46 Today Deutsche Bank
General Motors named short-term investment idea at Deutsche Bank
08/04/21 Citi
GM reaction 'appears excessive' after 'noisier' than expected Q2, says Citi
08/04/21 Wells Fargo
Wells Fargo expects GM to trade down modestly despite headline beat and raise
08/04/21 Credit Suisse
General Motors' lower 2H outlook 'a reset on expectations,' says Credit Suisse
GM General Motors
$52.71 /

-5.21 (-9.00%)

GM General Motors
$52.71 /

-5.21 (-9.00%)

GM General Motors
$52.71 /

-5.21 (-9.00%)

GM General Motors
$52.71 /

-5.21 (-9.00%)

Earnings
Focus Financial reports Q2 adjusted EPS with tax adjustments 98c, consensus 95c » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
FOCS

Focus Financial

$51.64 /

-0.07 (-0.14%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FOCS Focus Financial
$51.64 /

-0.07 (-0.14%)

FOCS Focus Financial
$51.64 /

-0.07 (-0.14%)

02/19/21 Keefe Bruyette
Focus Financial price target raised to $61 from $54 at Keefe Bruyette
FOCS Focus Financial
$51.64 /

-0.07 (-0.14%)

  • 22
    Jun
  • 26
    Feb
FOCS Focus Financial
$51.64 /

-0.07 (-0.14%)

Initiation
NewAge assumed with a Buy at Roth Capital » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
NBEV

NewAge

$1.94 /

-0.045 (-2.27%)

Roth Capital analyst Sean…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NBEV NewAge
$1.94 /

-0.045 (-2.27%)

NBEV NewAge
$1.94 /

-0.045 (-2.27%)

03/04/21 Roth Capital
NewAge's LOI to acquire Aliven strengthens Buy thesis, says Roth Capital
NBEV NewAge
$1.94 /

-0.045 (-2.27%)

Hot Stocks
Radius Health reiterates 2021 Adjusted EBITDA view of $10M » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
RDUS

Radius Health

$14.31 /

-0.28 (-1.92%)

Reduces TYMLOS revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RDUS Radius Health
$14.31 /

-0.28 (-1.92%)

RDUS Radius Health
$14.31 /

-0.28 (-1.92%)

03/22/21 Goldman Sachs
Radius Health assumed with a Buy at Goldman Sachs
02/24/21 H.C. Wainwright
Radius Health price target raised to $25 from $22 at H.C. Wainwright
01/07/21 Citi
Radius Health price target raised to $30 from $25 at Citi
10/22/20 H.C. Wainwright
Radius Health price target lowered to $22 from $28 at H.C. Wainwright
RDUS Radius Health
$14.31 /

-0.28 (-1.92%)

Earnings
Albemarle raises FY21 EPS view to $3.35-3.70 from $3.25-$3.65, consensus $3.61 » 07:09
08/05/21
08/05
07:09
08/05/21
07:09
ALB

Albemarle

$206.95 /

+0.085 (+0.04%)

As part of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALB Albemarle
$206.95 /

+0.085 (+0.04%)

ALB Albemarle
$206.95 /

+0.085 (+0.04%)

07/20/21 Loop Capital
Albemarle price target raised to $208 from $199 at Loop Capital
07/15/21 Deutsche Bank
Albemarle named 'Catalyst Call: Buy Idea' at Deutsche Bank
05/13/21 RBC Capital
Albemarle upgraded to Sector Perform from Underperform at RBC Capital
05/13/21 RBC Capital
Albemarle upgraded to Sector Perform from Underperform at RBC Capital
ALB Albemarle
$206.95 /

+0.085 (+0.04%)

  • 04
    Feb
ALB Albemarle
$206.95 /

+0.085 (+0.04%)

ALB Albemarle
$206.95 /

+0.085 (+0.04%)

ALB Albemarle
$206.95 /

+0.085 (+0.04%)

Earnings
PAE backs 2021 revenue view $3.05B-$3.15B, consensus $3.1B » 07:08
08/05/21
08/05
07:08
08/05/21
07:08
PAE

PAE

$8.33 /

-0.3 (-3.48%)

Still sees 2021 adjusted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAE PAE
$8.33 /

-0.3 (-3.48%)

PAE PAE
$8.33 /

-0.3 (-3.48%)

03/17/21 Deutsche Bank
PAE downgraded on 'unexpected' CEO change at Deutsche Bank
03/17/21 Deutsche Bank
PAE downgraded to Hold from Buy at Deutsche Bank
12/28/20 Morgan Stanley
PAE initiated with an Overweight at Morgan Stanley
PAE PAE
$8.33 /

-0.3 (-3.48%)

Recommendations
Ryman Hospitality price target raised to $95 from $88 at Deutsche Bank » 07:07
08/05/21
08/05
07:07
08/05/21
07:07
RHP

Ryman Hospitality

$74.35 /

-2.44 (-3.18%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RHP Ryman Hospitality
$74.35 /

-2.44 (-3.18%)

07/12/21 Raymond James
Ryman Hospitality upgraded to Outperform from Market Perform at Raymond James
07/12/21 Raymond James
Ryman Hospitality upgraded to Outperform from Market Perform at Raymond James
03/18/21 Truist
Ryman Hospitality price target raised to $50 from $47 at Truist
01/12/21 Raymond James
Ryman Hospitality downgraded to Market Perform from Outperform at Raymond James
RHP Ryman Hospitality
$74.35 /

-2.44 (-3.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.